Article Text
PDFClinical ethics
The winner takes it all
Statistics from Altmetric.com
We all make mistakes from time to time. I have made my fair share, but none of my mistakes have ever won a prize.
In 2002 Lundbeck breached the UK industry code of practice in the way it advertised escitalopram (Cipralex). Escitalopram is the son of citalopram (Cipramil). The company claimed that its new drug, escitalopram was more effective than citalopram, even though the two drugs have exactly the same active ingredient.1
The company was found to have breached the industry code, mainly by stating that “Cipralex is significantly more effective than Cipramil in treating depression”. The company also attributed side effects to citalopram in its literature on escitalopram that were not mentioned …
Read the full text or download the PDF:
Other content recommended for you
- Lundbeck broke advertising rules
- New drugs from old
- Prescription of proton pump inhibitors in older adults with complex polytherapy
- Who’s watching the watchdogs?
- News and updates from palliativedrugs.com
- Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs
- Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis
- Widening the debate about conflict of interest: addressing relationships between journalists and the pharmaceutical industry
- Making the best use of available evidence: the case of new generation antidepressants
- Risk of seizures with antidepressants: what is the evidence?